Selected multivariate analyses for EM, AM, and clinical outcomes
| . | GVH . | HVG . | ||||
|---|---|---|---|---|---|---|
| Outcome . | Adjusted HR . | 95% CI . | P . | Adjusted HR . | 95% CI . | P . |
| Multivariate analyses for class II EM | ||||||
| Relapse, all patients | 0.952 | 0.923-0.982 | .002 | — | — | — |
| Relapse, AML patients | 0.959 | 0.926-0.994 | .022 | — | — | — |
| RFS | 0.974 | 0.952-0.996 | .020 | — | — | — |
| Neutrophil engraftment | — | — | — | 0.974 | 0.954-0.995 | .013 |
| Platelet engraftment | — | — | — | 0.961 | 0.938-0.983 | .001 |
| Multivariate analyses for class II AM | ||||||
| Relapse, all patients | 0.645 | 0.451-0.924 | .017 | — | — | — |
| Platelet engraftment | — | — | — | 0.609 | 0.474-0.781 | <.001 |
| . | GVH . | HVG . | ||||
|---|---|---|---|---|---|---|
| Outcome . | Adjusted HR . | 95% CI . | P . | Adjusted HR . | 95% CI . | P . |
| Multivariate analyses for class II EM | ||||||
| Relapse, all patients | 0.952 | 0.923-0.982 | .002 | — | — | — |
| Relapse, AML patients | 0.959 | 0.926-0.994 | .022 | — | — | — |
| RFS | 0.974 | 0.952-0.996 | .020 | — | — | — |
| Neutrophil engraftment | — | — | — | 0.974 | 0.954-0.995 | .013 |
| Platelet engraftment | — | — | — | 0.961 | 0.938-0.983 | .001 |
| Multivariate analyses for class II AM | ||||||
| Relapse, all patients | 0.645 | 0.451-0.924 | .017 | — | — | — |
| Platelet engraftment | — | — | — | 0.609 | 0.474-0.781 | <.001 |
Multivariate analyses were conducted using marginal structural models with IPW. Covariates considered for adjustment were: male sex; age at transplant; donor age at transplant; presence of sex mismatch; CMV match status; donor relationship; presence of ablative regiment; disease status at transplant (active vs remission); refined DRI37 (low/intermediate vs high/very high); HCT-CI38 ; presence of DSAs; and presence of any class I or class II anti-HLA antibodies.
—, test not performed.